The Oncoguard® Liver test is a simple, yet sophisticated blood test offering a streamlined approach to HCC testing that can be integrated into your clinical workflow where it fits best for you. It delivers easy-to-interpret, actionable information in a single assessment.
A simplified testing pathway for most patients
The Oncoguard® Liver test is designed to be used in the clinical care pathway for at-risk patients.
Patients at risk for HCC
With Cirrhosis
Hepatitis B, C
Alcohol
Genetic hemochromatosis
Non-alcoholic fatty liver disease (NAFLD)
Stage 4 primary biliary cholangitis
Alpha-1-antitrypsin deficiency
Other causes of cirrhosis
Alcohol
Genetic hemochromatosis
Non-alcoholic fatty liver disease (NAFLD)
Stage 4 primary biliary cholangitis
Alpha-1-antitrypsin deficiency
Other causes of cirrhosis
Without Cirrhosis
Hepatitis B carriers (select)
HCC testing
Adapted from AASLD guideline1
Please note that the Oncoguard® Liver test is not currently recommended as part of the AASLD guideline.
The Oncoguard® Liver test is intended for the qualitative detection of biomarkers associated with HCC and is indicated as an aid in the detection of HCC for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC.
Applicability
The Oncoguard® Liver test was assessed in patients undergoing HCC testing with various disease etiologies. This included patients with cirrhosis due to HCV infection, HBV infection, and alcoholism, as well as non-cirrhotic HBV patients. The studies also included patients with disease etiologies that are on the rise, including non-alcoholic fatty liver disease (NAFLD). The test demonstrates strong performance across all disease etiologies, giving it broad applicability in clinical practice.
Consistency
A blood-based biomarker test like the Oncoguard® Liver test introduces a level of clarity and consistency you may not see with ultrasound assessments. Ultrasound sensitivity is often variable based on operator, equipment, and the patient’s overall morphology.1,2 Blood-based assessment offers consistency without concerns about patient weight, operator or equipment variability.
Convenience
The Oncoguard® Liver test requires a simple blood collection, enabling HCC testing from a single location. The convenience of a blood-based test may minimize the logistical challenges often encountered with traditional imaging procedures, helping more patients follow through with their care.
Let us help you get started
Contact the Customer Care Center at 1-844-870-8870 or fill out a form to request a visit with a representative.
The Oncoguard® Liver solution. Exactly what’s needed today.
Learn how to order the Oncoguard® Liver solution and interpret results.
References: 1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. 2. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169-177. doi:10.1111/apt.13841 3. Samoylova ML, Mehta N, Roberts JP, et al. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24(9):1171-1177. doi:10.1002/lt.25202